Table 2.

Demographic, clinical, and pathological baseline characteristics of our study population. Abbreviations: PPI, proton-pump inhibitor; EoE, eosinophilic esophagitis; PEC, peak eosinophilic count; EI, eosinophilic inflammation; BZH, basal zone hyperplasia; DIS, dilated intercellular spaces; LPF, lamina propria fibrosis; LP, lamina propria; EoEHSS, eosinophilic esophagitis histologic severity score; EREFS, endoscopic reference score; EGD, esophagogastroduodenoscopy; FSD, fibrostenotic disease. * Numbers are unique patient-based; ** Numbers are sample-based.

	All patients, n = 180	Adult, n = 92	Pediatric, n = 88
Clinical/demographic: *
Age (range)	26.9 (1.2–75.0)	43.0 (18–75.0)	12.4 (1.2–17.9)
Gender
Male	112 (62.2%)	50 (54.3%)	62 (70.5%)
Female	68 (37.8%)	42 (45.6%)	26 (29.5%)
Allergic disease	113 (62.7%)	50 (54.3%)	63 (71.5%)
Pre-biopsy treatment
Topical steroids	86 (47.7%)	36 (39.1%)	50 (56.8%)
PPI	60 (33.3%)	25 (27.1%)	35 (39.7%)
Dietary restriction	103 (57.2%)	48 (52.1%)	55 (62.5%)
Diagnosis of EoE	166 (92.2%)	81 (88.0%)	85 (96.5%)
Disease duration EoE patients, years (SD)	3.1 (10.0)	3.9 (13.7)	2.3 (3.2)
Histological features, avg. (SD): **
PEC	42.4 (31.7)	40.7 (31.9)	45.2 (30.7)
EI grade	2.0 (0.9)	2.0 (1.0)	2.2 (0.8)
EI stage	1.7 (1.1)	1.6 (1.1)	1.8 (1.1)
BZH grade	1.8 (1.0)	1.8 (1.0)	1.9 (0.9)
BZH stage	2.0 (1.1)	1.9 (1.1)	2.1 (1.0)
DIS grade	2.0 (1.1)	1.9 (1.2)	2.1 (1.1)
DIS stage	1.6 (1.1)	1.5 (1.0)	1.7 (1.0)
LPF grade	1.4 (1.1)	1.3 (1.1)	1.6 (1.0)
LPF stage	1.3 (1.1)	1.2 (1.1)	1.5 (1.1)
Total EoEHSS	12.4 (6.4)	12.1 (6.7)	13.2 (5.9)
EREFS (index endoscopy).
Total EREFS	2.4 (1.7)	2.4 (1.9)	2.5 (1.7)
Strictures before index EGD*	7 (3.8)	7 (3.8)	0 (0.0)
Strictures on index EGD*	23 (12.7)	20 (11.1)	3 (1.6)
Strictures on follow-up EGD*	24 (13.3)	20 (11.1)	4 (2.2)
FSD requiring dilatation on follow-up EGD*	23 (12.7)	20 (11.1)	3 (1.6)